https://scholars.lib.ntu.edu.tw/handle/123456789/458245
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | Chou H.-H | en_US |
dc.contributor.author | Wang K.-L | en_US |
dc.contributor.author | CHI-AN CHEN | en_US |
dc.contributor.author | LING-HUNG WEI | en_US |
dc.contributor.author | Lai C.-H | en_US |
dc.contributor.author | CHANG-YAO HSIEH | en_US |
dc.contributor.author | Yang Y.-C | en_US |
dc.contributor.author | Twu N.-F | en_US |
dc.contributor.author | Chang T.-C | en_US |
dc.contributor.author | Yen M.-S. | en_US |
dc.creator | Yen M.-S.;Chang T.-C;Twu N.-F;Yang Y.-C;Hsieh C.-Y;Lai C.-H;LING-HUNG WEI;Chen C.-A;Wang K.-L;Chou H.-H | - |
dc.date.accessioned | 2020-02-12T05:48:31Z | - |
dc.date.available | 2020-02-12T05:48:31Z | - |
dc.date.issued | 2006 | - |
dc.identifier.issn | 0090-8258 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/458245 | - |
dc.description.abstract | Objectives.: To evaluate the efficacy and safety of a distearoylphosphatidylcholine pegylated liposomal doxorubicin, Lipo-Dox?, in platinum-resistant or refractory epithelial ovarian cancer. Methods.: A multicenter phase II trial enrolled women with platinum-resistant or refractory epithelial ovarian carcinoma and na?ve to anthracycline. Eligible patients had either measurable tumor(s) or elevated serum CA 125 titer. Lipodox was initiated with a dose of 45 mg/m2 at a 4-week interval with subsequent escalation or reduction. A total of six cycles were scheduled. Results.: 29 patients, 20 with platinum-resistant and 9 with platinum refractory tumors, were enrolled. Lipo-Dox was given for an average of 4.6 cycles per patient with a total of 134 cycles. Among the 26 evaluable patients, one achieved CR, 5 PR and 9 SD. The overall response rate was 23.1% (95% CI, 6.8%-39.3%) with a median response duration of 11.6 weeks. 5 of the 6 responses were in patients with resistant disease. The median progression-free duration in the SD patients was 25.7 weeks. With a median follow-up of 13.8 months, the median progression-free and median overall survivals in the 26 patients were 5.4 months and 13.8 months, respectively. Hand-foot skin reaction occurred in 4.5% and skin pigmentation in 11.2% of all treatment cycles, all were Grade 1/2. Nausea and vomiting occurred in 14.2%, while anemia, leukopenia and thrombocytopenia occurred in 20.9%, 32.8% and 9% of cycle, respectively, and were mostly Grade 1 or 2. Conclusion.: Lipo-Dox, the third liposome encapsulated doxorubicin, at 45 mg/m2 every 4 weeks, is effective against recurrent, platinum-resistant epithelial ovarian cancers. ? 2005 Elsevier Inc. All rights reserved. | en_US |
dc.relation.ispartof | Gynecologic Oncology | en_US |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | CA 125 antigen; doxorubicin; platinum; adult; aged; anemia; article; cancer grading; cancer growth; cancer resistance; cancer survival; clinical article; clinical trial; controlled clinical trial; controlled study; drug efficacy; drug safety; female; follow up; gynecology; human; leukopenia; long term care; multicenter study; nausea and vomiting; oncology; ovary carcinoma; priority journal; skin manifestation; skin pigmentation; Taiwan; thrombocytopenia; time; Adult; Aged; Antibiotics, Antineoplastic; Doxorubicin; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Polyethylene Glycols | - |
dc.title | Pegylated liposomal doxorubicin (Lipo-Dox®) for platinum-resistant or refractory epithelial ovarian carcinoma: A Taiwanese gynecologic oncology group study with long-term follow-up | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1016/j.ygyno.2005.10.027 | - |
dc.identifier.pmid | 16325239 | - |
dc.identifier.scopus | 2-s2.0-33646559501 | - |
dc.relation.pages | 423-428 | en_US |
dc.relation.journalvolume | 101 | en_US |
dc.relation.journalissue | 3 | en_US |
item.openairetype | journal article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.cerifentitytype | Publications | - |
item.fulltext | no fulltext | - |
item.grantfulltext | none | - |
crisitem.author.dept | Obstetrics & Gynecology-NTUH | - |
crisitem.author.dept | Obstetrics & Gynecology | - |
crisitem.author.dept | Obstetrics & Gynecology | - |
crisitem.author.dept | Obstetrics & Gynecology-NTUH | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.dept | Obstetrics & Gynecology-NTUH | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.dept | Obstetrics & Gynecology | - |
crisitem.author.orcid | 0000-0001-6670-7939 | - |
crisitem.author.orcid | 0000-0001-8789-0859 | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。